Categories
Gold US Market

Kuros Biosciences Reports Results for the Full Year 2020

Kuros Biosciences Reports Results for the Full Year 2020

Sumary of Kuros Biosciences Reports Results for the Full Year 2020:

  • SCHLIEREN (ZURICH), Switzerland, March 18, 2021 (GLOBE NEWSWIRE) — Kuros Biosciences closed the year with outstanding results for 2020, accelerating sales by 58% and initiating the Phase II study for Fibrin PTH, confirming its successful transition into a fully-fledged orthobiologics company with scientific, clinical, and commercial excellence in bone regeneration…
  • Kuros raised gross proceeds of CHF 18.6 million from a capital increase to advance its pipeline, in particular the Phase II clinical study of its proprietary Fibrin-PTH product candidate in spinal fusion, and to progress commercialization of MagnetOs in the U.S…
  • Beyond this, we have started the Phase II with Fibrin-PTH in spinal fusion, which represents a huge commercial opportunity.”..
  • First patient treated in the STRUCTURE trial, investigating Fibrin-PTH for transforaminal lumbar interbody fusion (TLIF) procedures in patients with degenerative disc disease…
  • Won the 2020 Spine Technology Award, awarded by the widely-read industry publication Orthopedics This Week for outstanding innovations in the field, for its Fibrin-PTH technology Added to the body of data supporting the use of MagnetOs as an alternative to gold standard treatment autograft….

Want to know more click here go to source.